Johnson & Johnson on Tuesday topped analysts’ estimates for quarterly profit and revenue, driven by higher sales of rare-disease treatments from its acquisition of Actelion and cancer drugs Zytiga and Darzalex.
Source:: Reuters – Business News
Johnson & Johnson on Tuesday topped analysts’ estimates for quarterly profit and revenue, driven by higher sales of rare-disease treatments from its acquisition of Actelion and cancer drugs Zytiga and Darzalex.
Source:: Reuters – Business News
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.